These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 32379447)
21. MMpI: A WideRange of Available Compounds of Matrix Metalloproteinase Inhibitors. Muvva C; Patra S; Venkatesan S PLoS One; 2016; 11(8):e0159321. PubMed ID: 27509041 [TBL] [Abstract][Full Text] [Related]
22. Biphenyl substituted lysine derivatives as recognition elements for the matrix metalloproteinases MMP-2 and MMP-9. Kirchhain A; Zubrienė A; Kairys V; Vivaldi F; Bonini A; Biagini D; Santalucia D; Matulis D; Di Francesco F Bioorg Chem; 2021 Oct; 115():105155. PubMed ID: 34303036 [TBL] [Abstract][Full Text] [Related]
23. Is there new hope for therapeutic matrix metalloproteinase inhibition? Vandenbroucke RE; Libert C Nat Rev Drug Discov; 2014 Dec; 13(12):904-27. PubMed ID: 25376097 [TBL] [Abstract][Full Text] [Related]
24. Drug Design Inspired by Nature: Crystallographic Detection of an Auto-Tailored Protease Inhibitor Template. Gall FM; Hohl D; Frasson D; Wermelinger T; Mittl PRE; Sievers M; Riedl R Angew Chem Int Ed Engl; 2019 Mar; 58(12):4051-4055. PubMed ID: 30615822 [TBL] [Abstract][Full Text] [Related]
25. Gene expression levels of matrix metalloproteinases in human atherosclerotic plaques and evaluation of radiolabeled inhibitors as imaging agents for plaque vulnerability. Müller A; Krämer SD; Meletta R; Beck K; Selivanova SV; Rancic Z; Kaufmann PA; Vos B; Meding J; Stellfeld T; Heinrich TK; Bauser M; Hütter J; Dinkelborg LM; Schibli R; Ametamey SM Nucl Med Biol; 2014 Aug; 41(7):562-9. PubMed ID: 24853402 [TBL] [Abstract][Full Text] [Related]
26. Targeting matrix metalloproteinases: exploring the dynamics of the s1' pocket in the design of selective, small molecule inhibitors. Fabre B; Ramos A; de Pascual-Teresa B J Med Chem; 2014 Dec; 57(24):10205-19. PubMed ID: 25265401 [TBL] [Abstract][Full Text] [Related]
27. A comparative docking study and the design of potentially selective MMP inhibitors. Hanessian S; Moitessier N; Therrien E J Comput Aided Mol Des; 2001 Oct; 15(10):873-81. PubMed ID: 11918074 [TBL] [Abstract][Full Text] [Related]
28. Potential clinical applications of matrix metalloproteinase inhibitors and their future prospects. Li W; Saji S; Sato F; Noda M; Toi M Int J Biol Markers; 2013 Jun; 28(2):117-30. PubMed ID: 23787494 [TBL] [Abstract][Full Text] [Related]
29. Understanding the variability of the S1' pocket to improve matrix metalloproteinase inhibitor selectivity profiles. Gimeno A; Beltrán-Debón R; Mulero M; Pujadas G; Garcia-Vallvé S Drug Discov Today; 2020 Jan; 25(1):38-57. PubMed ID: 31513929 [TBL] [Abstract][Full Text] [Related]
30. An integrated computational and experimental approach to gaining selectivity for MMP-2 within the gelatinase subfamily. Fabre B; Filipiak K; Díaz N; Zapico JM; Suárez D; Ramos A; de Pascual-Teresa B Chembiochem; 2014 Feb; 15(3):399-412. PubMed ID: 24449516 [TBL] [Abstract][Full Text] [Related]
31. Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors. Foley LH; Palermo R; Dunten P; Wang P Bioorg Med Chem Lett; 2001 Apr; 11(8):969-72. PubMed ID: 11327602 [TBL] [Abstract][Full Text] [Related]
32. Specific interactions between zinc metalloproteinase and its inhibitors: Ab initio fragment molecular orbital calculations. Ara A; Kadoya R; Ishimura H; Shimamura K; Sylte I; Kurita N J Mol Graph Model; 2017 Aug; 75():277-286. PubMed ID: 28618335 [TBL] [Abstract][Full Text] [Related]
33. Fluorinated matrix metalloproteinases inhibitors--Phosphonate based potential probes for positron emission tomography. Beutel B; Daniliuc CG; Riemann B; Schäfers M; Haufe G Bioorg Med Chem; 2016 Feb; 24(4):902-9. PubMed ID: 26810711 [TBL] [Abstract][Full Text] [Related]
34. Multiple receptor-ligand based pharmacophore modeling and molecular docking to screen the selective inhibitors of matrix metalloproteinase-9 from natural products. Gao Q; Wang Y; Hou J; Yao Q; Zhang J J Comput Aided Mol Des; 2017 Jul; 31(7):625-641. PubMed ID: 28623487 [TBL] [Abstract][Full Text] [Related]
35. Discovery of dehydroabietic acid sulfonamide based derivatives as selective matrix metalloproteinases inactivators that inhibit cell migration and proliferation. Huang RZ; Liang GB; Huang XC; Zhang B; Zhou MM; Liao ZX; Wang HS Eur J Med Chem; 2017 Sep; 138():979-992. PubMed ID: 28756264 [TBL] [Abstract][Full Text] [Related]
36. Mechanisms of Action of Novel Drugs Targeting Angiogenesis-Promoting Matrix Metalloproteinases. Fields GB Front Immunol; 2019; 10():1278. PubMed ID: 31214203 [TBL] [Abstract][Full Text] [Related]
37. Similarity of binding sites of human matrix metalloproteinases. Lukacova V; Zhang Y; Mackov M; Baricic P; Raha S; Calvo JA; Balaz S J Biol Chem; 2004 Apr; 279(14):14194-200. PubMed ID: 14732707 [TBL] [Abstract][Full Text] [Related]
38. Enzymatic inhibitory activity of iridoid glycosides from Picrorrhiza kurroa against matrix metalloproteinases: Correlating in vitro targeted screening and docking. Rathee D; Lather V; Grewal AS; Dureja H Comput Biol Chem; 2019 Feb; 78():28-36. PubMed ID: 30497018 [TBL] [Abstract][Full Text] [Related]
39. In vitro biological evaluation of glyburide as potential inhibitor of collagenases. Bodiga VL; Eda SR; Chavali S; Revur NN; Zhang A; Thokala S; Bodiga S Int J Biol Macromol; 2014 Sep; 70():187-92. PubMed ID: 25008133 [TBL] [Abstract][Full Text] [Related]
40. N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity. Nuti E; Cantelmo AR; Gallo C; Bruno A; Bassani B; Camodeca C; Tuccinardi T; Vera L; Orlandini E; Nencetti S; Stura EA; Martinelli A; Dive V; Albini A; Rossello A J Med Chem; 2015 Sep; 58(18):7224-40. PubMed ID: 26263024 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]